🚀 VC round data is live in beta, check it out!
Kezar Life Sciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Kezar Life Sciences and similar public comparables like Mira Pharmaceuticals, THX Pharma, Pentixapharm Holding, Cantourage Group and more.
Kezar Life Sciences Overview
About Kezar Life Sciences
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
Founded
2015
HQ
Employees
55
Website
Sectors
Financials (LTM)
Market Cap
$54M
Kezar Life Sciences Financials
Kezar Life Sciences reported last 12-month revenue of —.
In the same LTM period, Kezar Life Sciences generated — in gross profit and had net loss of ($56M).
Revenue (LTM)
Kezar Life Sciences P&L
In the most recent fiscal year, Kezar Life Sciences reported revenue of — and EBITDA of ($81M).
Kezar Life Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($81M) | XXX | XXX | XXX |
| Net Profit | ($56M) | XXX | ($84M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Kezar Life Sciences Stock Performance
Kezar Life Sciences has current market cap of $54M.
Market Cap Evolution
Kezar Life Sciences' stock price is $7.31.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $54M | 0.0% | XXX | XXX | XXX | $-11.43 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKezar Life Sciences Valuation Multiples
Kezar Life Sciences trades at 0.3x EV/EBITDA.
EV / Revenue (LTM)
Kezar Life Sciences Financial Valuation Multiples
As of March 21, 2026, Kezar Life Sciences has market cap of $54M.
Equity research analysts estimate Kezar Life Sciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kezar Life Sciences has a P/E ratio of (0.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $54M | XXX | $54M | XXX | XXX | XXX |
| EV (current) | ($27M) | XXX | ($27M) | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 0.3x | XXX | XXX | XXX |
| EV/EBIT | 0.5x | XXX | 0.3x | XXX | XXX | XXX |
| P/E | (0.9x) | XXX | (0.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Kezar Life Sciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Kezar Life Sciences Margins & Growth Rates
Kezar Life Sciences' revenue in the last fiscal year declined by (100%).
Kezar Life Sciences' revenue per employee in the last FY averaged $0.0M.
Kezar Life Sciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (18%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Kezar Life Sciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Mira Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| THX Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pentixapharm Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Cantourage Group | XXX | XXX | XXX | XXX | XXX | XXX |
| ProMIS Neurosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kezar Life Sciences M&A Activity
Kezar Life Sciences acquired XXX companies to date.
Last acquisition by Kezar Life Sciences was on XXXXXXXX, XXXXX. Kezar Life Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Kezar Life Sciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialKezar Life Sciences Investment Activity
Kezar Life Sciences invested in XXX companies to date.
Kezar Life Sciences made its latest investment on XXXXXXXX, XXXXX. Kezar Life Sciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Kezar Life Sciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Kezar Life Sciences
| When was Kezar Life Sciences founded? | Kezar Life Sciences was founded in 2015. |
| Where is Kezar Life Sciences headquartered? | Kezar Life Sciences is headquartered in United States. |
| How many employees does Kezar Life Sciences have? | As of today, Kezar Life Sciences has over 55 employees. |
| Who is the CEO of Kezar Life Sciences? | Kezar Life Sciences' CEO is Christopher Kirk. |
| Is Kezar Life Sciences publicly listed? | Yes, Kezar Life Sciences is a public company listed on Nasdaq. |
| What is the stock symbol of Kezar Life Sciences? | Kezar Life Sciences trades under KZR ticker. |
| When did Kezar Life Sciences go public? | Kezar Life Sciences went public in 2018. |
| Who are competitors of Kezar Life Sciences? | Kezar Life Sciences main competitors are Mira Pharmaceuticals, THX Pharma, Pentixapharm Holding, Cantourage Group. |
| What is the current market cap of Kezar Life Sciences? | Kezar Life Sciences' current market cap is $54M. |
| Is Kezar Life Sciences profitable? | No, Kezar Life Sciences is not profitable. |
| What is the current net income of Kezar Life Sciences? | Kezar Life Sciences' last 12 months net income is ($56M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.